PubRank

David E Gilham

Author PubWeight™ 30.19‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens. J Immunother 2005 1.50
2 Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival. Cancer Immunol Immunother 2007 1.32
3 Natural expression of the CD19 antigen impacts the long-term engraftment but not antitumor activity of CD19-specific engineered T cells. J Immunol 2010 1.25
4 O6-Methylguanine-DNA methyltransferase inactivation and chemotherapy. Br Med Bull 2008 1.21
5 Building better chimeric antigen receptors for adoptive T cell therapy. Curr Gene Ther 2010 1.10
6 Development of adoptive cell therapy for cancer: a clinical perspective. Hum Gene Ther 2010 1.03
7 CAR T cells: driving the road from the laboratory to the clinic. Immunol Rev 2014 1.03
8 T regulatory cells in cancer: recent advances and therapeutic potential. Expert Opin Biol Ther 2010 1.02
9 The combination of cyclophosphamide and human T cells genetically engineered to target CD19 can eradicate established B-cell lymphoma. Br J Haematol 2008 1.02
10 Killing of non-Hodgkin lymphoma cells by autologous CD19 engineered T cells. Br J Haematol 2005 1.00
11 The optimal antigen response of chimeric antigen receptors harboring the CD3zeta transmembrane domain is dependent upon incorporation of the receptor into the endogenous TCR/CD3 complex. J Immunol 2010 0.99
12 Targeted immunotherapy of cancer with CAR T cells: achievements and challenges. Cancer Immunol Immunother 2012 0.98
13 T cell activation by antibody-like immunoreceptors: the position of the binding epitope within the target molecule determines the efficiency of activation of redirected T cells. J Immunol 2007 0.98
14 Vaccine and antibody-directed T cell tumour immunotherapy. Biochim Biophys Acta 2004 0.93
15 Eotaxin-2 and colorectal cancer: a potential target for immune therapy. Clin Cancer Res 2007 0.93
16 Functional expression of secreted proteins from a bicistronic retroviral cassette based on foot-and-mouth disease virus 2A can be position dependent. Hum Gene Ther 2010 0.93
17 Chimeric antigen receptors for T-cell based therapy. Methods Mol Biol 2012 0.92
18 Eradication of established B-cell lymphoma by CD19-specific murine T cells is dependent on host lymphopenic environment and can be mediated by CD4+ and CD8+ T cells. J Immunother 2009 0.90
19 Combination of vaccination and chimeric receptor expressing T cells provides improved active therapy of tumors. J Immunol 2006 0.90
20 Engineering T-cells with antibody-based chimeric receptors for effective cancer therapy. Curr Opin Mol Ther 2005 0.87
21 Adoptive transfer of T(reg) depleted autologous T cells in advanced renal cell carcinoma. Cancer Immunol Immunother 2007 0.85
22 Development of a flow cytometric co-immunoprecipitation technique for the study of multiple protein-protein interactions and its application to T-cell receptor analysis. Cytometry A 2010 0.85
23 Potential limitations of the NSG humanized mouse as a model system to optimize engineered human T cell therapy for cancer. Hum Gene Ther Methods 2013 0.84
24 Gene therapy of patient-derived T lymphocytes to target and eradicate colorectal hepatic metastases. Dis Colon Rectum 2003 0.84
25 Gene delivery of a mutant TGFβ3 reduces markers of scar tissue formation after cutaneous wounding. Mol Ther 2010 0.84
26 Regulation of autologous immunity to the mouse 5T4 oncofoetal antigen: implications for immunotherapy. Cancer Immunol Immunother 2011 0.84
27 Differential role of Th1 and Th2 cytokines in autotoxicity driven by CD19-specific second-generation chimeric antigen receptor T cells in a mouse model. J Immunol 2014 0.82
28 Rapid high-performance liquid chromatographic analysis of adenovirus type 5 particles with a prototype anion-exchange analytical monolith column. J Chromatogr A 2008 0.80
29 Definition and application of good manufacturing process-compliant production of CEA-specific chimeric antigen receptor expressing T-cells for phase I/II clinical trial. Cancer Immunol Immunother 2013 0.80
30 Targeting breast cancer vaccines to dendritic cells: improved immunological responses with less protein? Breast Cancer Res 2012 0.79
31 In vitro effect of IL-2 in combination with pazopanib or sunitinib on lymphocytes function and apoptosis of RCC cells. Expert Opin Pharmacother 2014 0.77
32 Isolation of tumor antigen-specific single-chain variable fragments using a chimeric antigen receptor bicistronic retroviral vector in a Mammalian screening protocol. Hum Gene Ther Methods 2013 0.76
33 Cellular therapy of cancer symposium December 2nd-3rd 2006 Manchester, UK. Cancer Immunol Immunother 2007 0.75
34 Clinical Grade Manufacture of CYAD-101, a NKG2D-based, First in Class, Non-Gene-edited Allogeneic CAR T-Cell Therapy. J Immunother 2022 0.75
35 Genetic modification of mouse effector and helper T lymphocytes expressing a chimeric antigen receptor. Methods Mol Biol 2014 0.75
36 The second cellular therapy of cancer symposium, 27-29 March 2009, Milan, Italy. Cancer Immunol Immunother 2009 0.75